Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis

被引:298
作者
Taylor, Peter C. [1 ]
Feldmann, Marc [1 ]
机构
[1] Univ London Imperial Coll Sci Technol & Med, Div Rheumatol, Kennedy Inst, London, England
关键词
TUMOR-NECROSIS-FACTOR; INTERLEUKIN-1 RECEPTOR ANTAGONIST; COLLAGEN-INDUCED ARTHRITIS; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; FACTOR-ALPHA; COMBINATION THERAPY; PLUS METHOTREXATE; CLINICAL-TRIAL; PHASE-III;
D O I
10.1038/nrrheum.2009.181
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Cytokines such as tumor necrosis factor (TNF) are expressed at high levels in rheumatoid joint tissue, where they contribute significantly to inflammation and articular destruction. TNF was the first cytokine to be fully validated as a therapeutic target for rheumatoid arthritis (RA). In nearly a decade since anti-TNF agents-such as infliximab, etanercept and adalimumab-were launched as the first biologic therapies to be licensed for RA, much has been learnt about how and when in the disease course this class of drug can be used to achieve optimal therapeutic benefit. Other cytokine targets, such as interleukin (IL)-6 or IL-1, have also been validated and several are in the process of being tested. However, TNF is likely to remain the preferred target of first-line biologic therapy for the foreseeable future as, in populations with active RA despite ongoing, nonbiologic, DMARD therapy, biologic inhibition of either IL-6 or IL-1 demonstrates no obviously superior outcomes to TNF blockade. Furthermore, new approaches to blockade of signaling mediated by bioactive TNF might have the potential to generate higher-magnitude clinical responses than are currently elicited.
引用
收藏
页码:578 / 582
页数:5
相关论文
共 60 条
[1]   The safety of anti-tumour necrosis factor therapy in rheumatoid arthritis [J].
Askling, Johan ;
Dixon, Will .
CURRENT OPINION IN RHEUMATOLOGY, 2008, 20 (02) :138-144
[2]  
Augustsson J., 2010, Annals of the rheumatic diseases
[3]   Targeting interleukin-15 in patients with rheumatoid arthritis - A proof-of-concept study [J].
Baslund, B ;
Tvede, N ;
Danneskiold-Samsoe, B ;
Larsson, P ;
Panayi, G ;
Petersen, J ;
Petersen, LJ ;
Beurskens, FJM ;
Schuurman, J ;
van de Winkel, JGJ ;
Parren, PWHI ;
Gracie, JA ;
Jongbloed, S ;
Liew, FY ;
McInnes, IB .
ARTHRITIS AND RHEUMATISM, 2005, 52 (09) :2686-2692
[4]   Effect of the Early Use of the Anti-Tumor Necrosis Factor Adalimumab on the Prevention of Job Loss in Patients With Early Rheumatoid Arthritis [J].
Bejarano, Victoria ;
Quinn, Mark ;
Conaghan, Philip G. ;
Reece, Richard ;
Keenan, Anne-Maree ;
Walker, David ;
Gough, Andrew ;
Green, Michael ;
McGonagle, Dennis ;
Adebajo, Ade ;
Jarrett, Stephen ;
Doherty, Sheelagh ;
Hordon, Lesley ;
Melsom, Richard ;
Unnebrink, Kristina ;
Kupper, Hartmut ;
Emery, Paul .
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2008, 59 (10) :1467-1474
[5]   STIMULATION OF BONE-RESORPTION AND INHIBITION OF BONE-FORMATION INVITRO BY HUMAN-TUMOR NECROSIS FACTORS [J].
BERTOLINI, DR ;
NEDWIN, GE ;
BRINGMAN, TS ;
SMITH, DD ;
MUNDY, GR .
NATURE, 1986, 319 (6053) :516-518
[6]   The PREMIER study - A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment [J].
Breedveld, FC ;
Weisman, MH ;
Kavanaugh, AF ;
Cohen, SB ;
Pavelka, K ;
van Vollenhoven, R ;
Sharp, J ;
Perez, JL ;
Spencer-Green, GT .
ARTHRITIS AND RHEUMATISM, 2006, 54 (01) :26-37
[7]   Modelling the cost effectiveness of TNF-α antagonists in the management of rheumatoid arthritis:: results from the British Society for Rheumatology Biologics Registry [J].
Brennan, A. ;
Bansback, N. ;
Nixon, R. ;
Madan, J. ;
Harrison, M. ;
Watson, K. ;
Symmons, D. .
RHEUMATOLOGY, 2007, 46 (08) :1345-1354
[8]  
BRENNAN FM, 1989, LANCET, V2, P244
[9]  
Bresnihan B, 1998, ARTHRITIS RHEUM, V41, P2196, DOI 10.1002/1529-0131(199812)41:12<2196::AID-ART15>3.3.CO
[10]  
2-U